ABERA BIOSCIENCE AB

Their core work

Abera Bioscience is a Swedish biotech SME based in Uppsala specializing in vaccine development against intracellular pathogens, with a particular focus on triggering CD8 T cell-mediated immune responses. Their work sits at the interface of vaccine technology and infectious disease biology, addressing pathogens that evade conventional antibody-based protection by hiding inside host cells. Beyond vaccine development, they have contributed to EU-wide antimicrobial resistance training programs, positioning themselves as both a research actor and an industry host for the next generation of infectious disease scientists. Their H2020 participation spans from structured doctoral training networks to applied vaccine research consortia, indicating they operate as a specialist industry partner within academic-led projects.

What they specialise in

How they've shifted over time

In the first half of their H2020 engagement (from 2016), Abera's involvement centered on broad antimicrobial resistance themes — drug discovery, resistance mechanisms, and excellence in training — through their third-party role in AIMMS STAR-PLUS. By 2019, their focus narrowed and deepened considerably: VacPath reveals a pivot toward vaccine vectors and cellular immunity, specifically CD8 T cell responses against intracellular pathogens. This is a meaningful shift from general antimicrobial awareness toward a more specialized, mechanistic approach to immune protection. The trajectory suggests a company that started as a training-network participant and is maturing into a defined vaccine technology niche.

Abera is moving toward a focused position in next-generation vaccines against hard-to-target intracellular pathogens — a space with growing relevance as traditional antibiotics and antibody therapies reach their limits against organisms like Mycobacteria, Salmonella, and Listeria.

How they like to work

Abera has not led any H2020 project as coordinator; they join consortia as a specialist partner or third party, which is typical for a small biotech that brings specific platform technology or disease expertise rather than project management capacity. Their two projects are both MSCA schemes — large, multi-partner training networks that typically involve 10–20 institutions — so they are comfortable operating inside complex academic-industry consortia. This suggests they make reliable, focused contributors rather than consortium architects, and prospective partners should expect them to engage deeply in their technical work package without taking on administrative lead roles.

Abera has built connections with 12 unique consortium partners across 7 countries through just two projects, suggesting each network was substantive rather than superficial. Their Uppsala base within Sweden's life science corridor likely gives them proximity to Karolinska, SciLifeLab, and other regional biomedical actors beyond what the CORDIS data captures.

What sets them apart

Abera occupies a specific and defensible niche: vaccine development targeting intracellular pathogens via T cell-mediated immunity, an area where most vaccine platforms underperform and where new vectors are urgently needed. As an SME, they offer the speed and focus that large pharma cannot, while their dual participation in MSCA training networks shows they are embedded in the academic research pipeline that feeds this field. For a consortium builder, Abera brings both proprietary platform knowledge and demonstrated ability to collaborate inside EU-funded research structures.

Highlights from their portfolio

• VacPath
  Their only funded H2020 project (EUR 281,983), it directly reflects Abera's core commercial focus on vaccine vectors and cellular immunity against intracellular pathogens — the most direct window into what the company actually builds.
• AIMMS STAR-PLUS
  A prestigious MSCA-COFUND doctoral training program in antimicrobial research running six years (2016-2022), placing Abera inside a Europe-wide excellence network for infectious disease science despite carrying no direct EC funding for them.